McConnell D J
J Clin Invest. 1972 Jul;51(7):1611-23. doi: 10.1172/jci106962.
Human plasma was fractionated by ammonium sulfate precipitation, DEAE-cellulose chromatography, and Sephadex G-200 gel filtration to determine which method would give the greatest number of clearly separable kallikrein inhibitory peaks. With G-200 gel filtration three peaks could be separated which were demonstrated to contain alpha(2)-macroglobulin, C1 inactivator, and alpha(1)-antitrypsin. No other kallikrein inhibitors could be identified. The fractions containing C1 inactivator and alpha(2)-macroglobulin appeared to be more effective against kallikrein than that containing alpha(1)-antitrypsin. A patient with hereditary angioneurotic edema was shown to have an abnormal C1 inactivator protein capable of interfering with kallikrein's biologic, but not its esterolytic activity. Heat-treated human plasma, a commonly used source of kininogen for experiments with kallikrein, was shown to have kallikrein inhibitory activity.
通过硫酸铵沉淀、二乙氨基乙基纤维素色谱法和葡聚糖凝胶G - 200凝胶过滤法对人血浆进行分级分离,以确定哪种方法能产生数量最多的可清晰分离的激肽释放酶抑制峰。采用G - 200凝胶过滤法可分离出三个峰,经证实分别含有α(2)-巨球蛋白、C1灭活剂和α(1)-抗胰蛋白酶。未鉴定出其他激肽释放酶抑制剂。含有C1灭活剂和α(2)-巨球蛋白的组分对激肽释放酶的抑制作用似乎比含有α(1)-抗胰蛋白酶的组分更强。一名遗传性血管性水肿患者被证明有一种异常的C1灭活剂蛋白,该蛋白能够干扰激肽释放酶的生物学活性,但不影响其酯解活性。热处理的人血浆是激肽释放酶实验中常用的激肽原来源,已证明其具有激肽释放酶抑制活性。